Reviva Pharmaceuticals Holdings, Inc. has entered into an At Market Issuance Sales Agreement with B. Riley Securities, Inc. and Alliance Global Partners. This agreement allows Reviva to offer and sell shares of its common stock, with a total value of up to $50 million, through an at-the-market offering program. The shares will be sold at the company's discretion, leveraging the agents' commercially reasonable efforts to facilitate the sales. The offering will be conducted under the company's shelf Registration Statement filed with the SEC, with an effective registration date in February 2024.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Reviva Pharmaceuticals Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-25-018972), on May 30, 2025, and is solely responsible for the information contained therein.